The global boom in start-up valuations has abruptly stopped. How can biotech start-ups buck this trend and create sustainable, valuable businesses over the long-term?
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.